Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ainos, Inc. stock logo
AIMD
Ainos
$3.82
-4.0%
$3.04
$2.00
$5.00
$17.79M2.27.18 million shs63,597 shs
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
$8.23
+5.2%
$8.07
$3.08
$597.60
$18.44M0.08201,338 shs96,729 shs
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
$0.88
-1.1%
$0.88
$0.77
$4.38
$17.22M0.79192,645 shs45,379 shs
Oragenics, Inc. stock logo
OGEN
Oragenics
$1.03
-7.9%
$1.58
$1.03
$38.70
$4.25M0.65318,914 shs119,318 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ainos, Inc. stock logo
AIMD
Ainos
0.00%+7.30%+46.92%+13.22%+21.02%
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
0.00%+3.00%-26.58%-66.73%-96.97%
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
0.00%+11.04%-2.19%-12.84%-69.85%
Oragenics, Inc. stock logo
OGEN
Oragenics
0.00%-7.21%-18.25%-71.39%-96.85%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Ainos, Inc. stock logo
AIMD
Ainos
1.0153 of 5 stars
0.03.00.00.04.31.70.0
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
1.1213 of 5 stars
0.04.00.00.02.72.50.0
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
3.7232 of 5 stars
3.55.00.00.03.13.30.6
Oragenics, Inc. stock logo
OGEN
Oragenics
0.1137 of 5 stars
0.04.00.00.00.60.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ainos, Inc. stock logo
AIMD
Ainos
0.00
N/AN/AN/A
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
2.00
HoldN/AN/A
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
3.00
Buy$4.00354.39% Upside
Oragenics, Inc. stock logo
OGEN
Oragenics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest OGEN, CYCC, AIMD, and LEXX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/29/2025
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$5.00 ➝ $4.00
7/1/2025
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$7.00 ➝ $5.00
(Data available from 8/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ainos, Inc. stock logo
AIMD
Ainos
$20K890.06N/AN/A$2.46 per share1.55
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
$40K460.88N/AN/A$1.62 per share5.08
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
$460K37.43N/AN/A$0.48 per share1.83
Oragenics, Inc. stock logo
OGEN
Oragenics
N/AN/AN/AN/A$0.61 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ainos, Inc. stock logo
AIMD
Ainos
-$14.86M-$4.99N/AN/AN/A-108.25%-56.94%11/4/2025 (Estimated)
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
-$11.21M-$839.58N/AN/AN/A-723.64%-145.51%11/10/2025 (Estimated)
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
-$5.80M-$0.67N/AN/AN/A-1,849.19%-157.22%-133.69%N/A
Oragenics, Inc. stock logo
OGEN
Oragenics
-$20.66M-$21.42N/AN/AN/A-2,087.95%-486.56%N/A

Latest OGEN, CYCC, AIMD, and LEXX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
Ainos, Inc. stock logo
AIMD
Ainos
N/A-$0.99N/A-$0.99N/AN/A
8/13/2025Q2 2025
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
-$72.00-$0.98+$71.02-$0.98$0.03 millionN/A
7/14/2025Q3 2025
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
-$0.15-$0.21-$0.06-$0.21$0.17 million$0.17 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Ainos, Inc. stock logo
AIMD
Ainos
N/AN/AN/AN/AN/A
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
N/AN/AN/AN/AN/A
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
N/AN/AN/AN/AN/A
Oragenics, Inc. stock logo
OGEN
Oragenics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ainos, Inc. stock logo
AIMD
Ainos
0.96
2.88
2.61
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
N/A
5.77
5.77
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
N/A
3.90
3.90
Oragenics, Inc. stock logo
OGEN
Oragenics
N/A
1.93
1.93

Institutional Ownership

CompanyInstitutional Ownership
Ainos, Inc. stock logo
AIMD
Ainos
N/A
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
23.58%
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
13.06%
Oragenics, Inc. stock logo
OGEN
Oragenics
18.71%

Insider Ownership

CompanyInsider Ownership
Ainos, Inc. stock logo
AIMD
Ainos
10.39%
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
51.20%
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
26.40%
Oragenics, Inc. stock logo
OGEN
Oragenics
4.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ainos, Inc. stock logo
AIMD
Ainos
404.66 million4.17 millionNot Optionable
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
142.24 million1.09 millionOptionable
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
719.56 million14.40 millionNot Optionable
Oragenics, Inc. stock logo
OGEN
Oragenics
54.13 million10.98 millionN/A

Recent News About These Companies

Oragenics Q2 2025 Shareholder Update
Sarasota biotech company announces $20M public offering
Oragenics Inc.

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Ainos stock logo

Ainos NASDAQ:AIMD

$3.82 -0.16 (-4.02%)
As of 08/29/2025 04:00 PM Eastern

Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.

Cyclacel Pharmaceuticals stock logo

Cyclacel Pharmaceuticals NASDAQ:CYCC

$8.23 +0.41 (+5.24%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$8.02 -0.22 (-2.61%)
As of 08/29/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.

Lexaria Bioscience stock logo

Lexaria Bioscience NASDAQ:LEXX

$0.88 -0.01 (-1.09%)
Closing price 08/29/2025 03:57 PM Eastern
Extended Trading
$0.89 +0.01 (+1.56%)
As of 08/29/2025 06:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.

Oragenics stock logo

Oragenics NYSE:OGEN

$1.03 -0.09 (-7.90%)
Closing price 08/29/2025 03:59 PM Eastern
Extended Trading
$1.06 +0.03 (+3.40%)
As of 08/29/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Oragenics, Inc., a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.